AUPQ014799A0 - Amplification of folate-mediated targeting to tumor cells using polymers - Google Patents
Amplification of folate-mediated targeting to tumor cells using polymersInfo
- Publication number
- AUPQ014799A0 AUPQ014799A0 AUPQ0147A AUPQ014799A AUPQ014799A0 AU PQ014799 A0 AUPQ014799 A0 AU PQ014799A0 AU PQ0147 A AUPQ0147 A AU PQ0147A AU PQ014799 A AUPQ014799 A AU PQ014799A AU PQ014799 A0 AUPQ014799 A0 AU PQ014799A0
- Authority
- AU
- Australia
- Prior art keywords
- folate
- amplification
- polymers
- tumor cells
- mediated targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B11/00—Preparation of cellulose ethers
- C08B11/20—Post-etherification treatments of chemical or physical type, e.g. mixed etherification in two steps, including purification
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/52—Amides or imides
- C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
- C08F220/58—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing oxygen in addition to the carbonamido oxygen, e.g. N-methylolacrylamide, N-(meth)acryloylmorpholine
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
- C08F251/02—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof on to cellulose or derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ0147A AUPQ014799A0 (en) | 1999-05-04 | 1999-05-04 | Amplification of folate-mediated targeting to tumor cells using polymers |
JP2000614977A JP2002543111A (en) | 1999-05-04 | 2000-05-04 | Amplification of folate-mediated targeting to tumor cells using polymers |
EP00920286A EP1206252A4 (en) | 1999-05-04 | 2000-05-04 | Amplification of folate-mediated targeting to tumor cells using polymers |
CA002372841A CA2372841A1 (en) | 1999-05-04 | 2000-05-04 | Amplification of folate-mediated targeting to tumor cells using polymers |
PCT/AU2000/000406 WO2000066091A1 (en) | 1999-05-04 | 2000-05-04 | Amplification of folate-mediated targeting to tumor cells using polymers |
AU40943/00A AU4094300A (en) | 1999-05-04 | 2000-05-04 | Amplification of folate-mediated targeting to tumor cells using polymers |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ0147A AUPQ014799A0 (en) | 1999-05-04 | 1999-05-04 | Amplification of folate-mediated targeting to tumor cells using polymers |
Publications (1)
Publication Number | Publication Date |
---|---|
AUPQ014799A0 true AUPQ014799A0 (en) | 1999-05-27 |
Family
ID=3814354
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AUPQ0147A Abandoned AUPQ014799A0 (en) | 1999-05-04 | 1999-05-04 | Amplification of folate-mediated targeting to tumor cells using polymers |
AU40943/00A Abandoned AU4094300A (en) | 1999-05-04 | 2000-05-04 | Amplification of folate-mediated targeting to tumor cells using polymers |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU40943/00A Abandoned AU4094300A (en) | 1999-05-04 | 2000-05-04 | Amplification of folate-mediated targeting to tumor cells using polymers |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1206252A4 (en) |
JP (1) | JP2002543111A (en) |
AU (2) | AUPQ014799A0 (en) |
CA (1) | CA2372841A1 (en) |
WO (1) | WO2000066091A1 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60231868D1 (en) | 2001-04-24 | 2009-05-20 | Purdue Research Foundation | FOLAT MIMETICS AND THEIR FOLAT RECEPTOR BINDING CONJUGATES |
CA2461877A1 (en) * | 2001-09-28 | 2003-04-10 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
ES2324708T3 (en) * | 2002-05-15 | 2009-08-13 | Endocyte, Inc. | VITAMIN-MYTHOMYCIN CONJUGATES. |
AU2002953073A0 (en) * | 2002-11-21 | 2003-01-16 | Access Pharmaceuticals Australia Pty Limited | Amplification of biotin-mediated targeting |
EP2529758A3 (en) * | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
EP1789391B1 (en) | 2004-07-23 | 2017-06-28 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
WO2006101845A2 (en) | 2005-03-16 | 2006-09-28 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
JP5475992B2 (en) * | 2005-08-19 | 2014-04-16 | エンドサイト,インコーポレイテッド | Multidrug ligand conjugate |
NZ609752A (en) | 2005-08-24 | 2014-08-29 | Immunogen Inc | Process for preparing maytansinoid antibody conjugates |
WO2007080114A2 (en) * | 2006-01-11 | 2007-07-19 | Biotech Igg Ab | Macromolecule conjugate |
AR062448A1 (en) * | 2006-05-25 | 2008-11-12 | Endocyte Inc | CONJUGATES OF ANALOGS OF AZIRIDINIL-EPOTILONE AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE SAME |
PE20080316A1 (en) | 2006-05-25 | 2008-04-10 | Bristol Myers Squibb Co | AZIRIDINYL-EPOTILONE COMPOUNDS |
WO2008101231A2 (en) * | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
JP5829793B2 (en) | 2007-03-14 | 2015-12-09 | エンドサイト・インコーポレイテッドEndocyte, Inc. | Drug delivery conjugates of tubricin bound by a binding ligand |
JP2010528122A (en) * | 2007-05-09 | 2010-08-19 | 日東電工株式会社 | Polymer combined with platinum drug |
US8143415B2 (en) | 2007-05-25 | 2012-03-27 | Bristol-Myers Squibb Company | Processes for making epothilone compounds and analogs |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
JP5690589B2 (en) | 2007-06-25 | 2015-03-25 | エンドサイト・インコーポレイテッドEndocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
AU2008289108C1 (en) | 2007-08-17 | 2024-05-23 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
AU2008316835B2 (en) | 2007-10-25 | 2015-07-16 | Endocyte, Inc. | Tubulysins and processes for preparing |
EP2274017B1 (en) * | 2008-04-30 | 2016-04-13 | Ben Gurion University Of The Negev Research And Development Authority | E-selectin specific vascular delivery systems |
US8546425B2 (en) | 2008-09-17 | 2013-10-01 | Purdue Research Foundation | Folate receptor binding conjugates of antifolates |
CA2739757C (en) | 2008-10-07 | 2016-07-05 | Rexahn Pharmaceuticals, Inc. | Hpma - docetaxel or gemcitabine conjugates and uses therefore |
EP2210616A1 (en) * | 2009-01-21 | 2010-07-28 | Centre National de la Recherche Scientifique | Multifunctional stealth nanoparticles for biomedical use |
SI2437790T1 (en) | 2009-06-03 | 2019-07-31 | Immunogen, Inc. | Conjugation methods |
JP5749273B2 (en) | 2009-10-13 | 2015-07-15 | レクサン ファーマシューティカルズ インコーポレイテッド | Polymer systems for anticancer drug delivery |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
MX369659B (en) * | 2011-03-29 | 2019-11-15 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process. |
WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
SG11201502429YA (en) | 2012-10-04 | 2015-04-29 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
BR112015008365A2 (en) | 2012-10-16 | 2017-07-04 | Endocyte Inc | compound of the formula bl (d) x, or a pharmaceutically acceptable salt thereof, pharmaceutical composition, use of a compound, unit dosage form or unit dose composition, composition for treating a cancer in a patient, and method for treating a cancer in a patient |
KR20150104092A (en) | 2012-11-15 | 2015-09-14 | 엔도사이트, 인코포레이티드 | Conjugates for treating diseases caused by psma expressing cells |
EP3415489A1 (en) | 2013-10-18 | 2018-12-19 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
CA2930581A1 (en) * | 2013-11-14 | 2015-05-21 | Endocyte, Inc. | Compounds for positron emission tomography |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
EP3472178A4 (en) | 2016-06-17 | 2020-02-19 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+cells |
CN106619571B (en) * | 2017-01-03 | 2020-04-07 | 西南交通大学 | Polymer nano-carrier for improving endocytosis and cell nucleus targeting and preparation method thereof |
CN110461876B (en) | 2017-01-20 | 2024-05-17 | 海德堡医药研究有限责任公司 | Compositions and methods for depleting cd137+ cells |
CA3095644A1 (en) * | 2018-03-29 | 2019-10-03 | Nof Corporation | Degradable polyethylene glycol conjugate |
AU2019264092B2 (en) * | 2018-05-04 | 2024-02-15 | Twinpigbiolab. Inc. | Targeting M2-like tumor-associated macrophages by using melittin-based pro-apoptotic peptide |
CN112608398B (en) * | 2020-11-30 | 2022-04-22 | 西安交通大学 | reduction/pH sensitive polysaccharide-based nano prodrug carrying adriamycin and platinum drugs together, and preparation method and application thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2044663A1 (en) * | 1990-07-12 | 1992-01-13 | Makoto Tanaka | Water-dispersible polyene antifungal complexes |
US5449720A (en) * | 1993-05-24 | 1995-09-12 | Biotech Australia Pty Limited | Amplification of the VB12 uptake system using polymers |
US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
GB9600272D0 (en) * | 1996-01-06 | 1996-03-06 | Univ Nottingham | Polymers |
TW520297B (en) * | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
ATE385778T1 (en) * | 1998-12-18 | 2008-03-15 | Hadasit Med Res Service | METHOD FOR ADMINISTRATION OF A COMPOUND TO MULTI-RESISTANT CELLS |
-
1999
- 1999-05-04 AU AUPQ0147A patent/AUPQ014799A0/en not_active Abandoned
-
2000
- 2000-05-04 AU AU40943/00A patent/AU4094300A/en not_active Abandoned
- 2000-05-04 WO PCT/AU2000/000406 patent/WO2000066091A1/en not_active Application Discontinuation
- 2000-05-04 JP JP2000614977A patent/JP2002543111A/en active Pending
- 2000-05-04 EP EP00920286A patent/EP1206252A4/en not_active Withdrawn
- 2000-05-04 CA CA002372841A patent/CA2372841A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU4094300A (en) | 2000-11-17 |
JP2002543111A (en) | 2002-12-17 |
EP1206252A1 (en) | 2002-05-22 |
EP1206252A4 (en) | 2005-02-16 |
WO2000066091A1 (en) | 2000-11-09 |
CA2372841A1 (en) | 2000-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AUPQ014799A0 (en) | Amplification of folate-mediated targeting to tumor cells using polymers | |
AUPQ014699A0 (en) | Amplification of folate-mediated targeting to tumor cells using nanoparticles | |
AU2001292728A1 (en) | Compositions and methods for identifying and targeting stomach and esophageal cancer cells | |
AU5731400A (en) | Methods of preparing electrochemical cells | |
AU1796601A (en) | Methods of preparing electrochemical cells | |
AU5481000A (en) | Combination cancer therapy comprising adenosine and deaminase enzyme inhibitor | |
AU2001288686A1 (en) | Improved cardiac function through administration of es cells | |
AU2171501A (en) | Improvements relating to double-stranded rna inhibition | |
AU1922301A (en) | Differential gene expression in cancer | |
AU2001231204A1 (en) | Genetically engineered tumor cell vaccines | |
HK1048820A1 (en) | Compositions and methods for double-targeting virus infections and targeting cancer cells | |
AU6208100A (en) | Cancer treatment using angiopoietins targeted to aminophospholipids | |
AU2002235168A1 (en) | Targeting pluripotent stem cells to tissues | |
AU2452197A (en) | Genes amplified in cancer cells | |
AU3881100A (en) | Human tumor necrosis factor receptor-like genes | |
AU6611500A (en) | Single-phase amplification of nucleic acids | |
AU1796501A (en) | Methods of preparing electrochemical cells | |
AU2135001A (en) | Targeting of endosomal growth factor processing as anti-cancer therapy | |
AU2001272967A1 (en) | Imaging and targeting tumors using sickle cells | |
AU2002224096A1 (en) | Method of testing anticancer agent-sensitivity of tumor cells | |
EP1218393A4 (en) | Cell targeting compositions and methods of using the same | |
GB0011060D0 (en) | Improvements relating to gene directed enzyme prodrug therapy | |
WO2002007681A3 (en) | Sunscreen formulations containing nucleic acids | |
AU2307000A (en) | Materials and methods relating to the detection of a cancer cell marker | |
AU4774200A (en) | Long term cell culture of human carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NAA1 | Application designating australia and claiming priority from australian document |
Ref document number: 4094300 Country of ref document: AU |
|
PC1 | Assignment before grant (sect. 113) |
Owner name: ACCESS PHARMACEUTICALS AUSTRALIA PTY. LTD. Free format text: THE FORMER OWNER WAS: BIOTECH AUSTRALIA PTY. LIMITED |